Press Releases

InVivo Therapeutics to Present at 2017 BIO CEO & Investor Conference

Published: February 7, 2017

CAMBRIDGE, Mass. (Feb 7, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the 2017 BIO CEO & Investor Conference on Monday, February 13, 2017 at 11:30 A.M. Eastern Time at the Waldorf Astoria in New York, NY. Mr. Perrin will highlight the recent progress of the Company’s Neuro-Spinal Scaffold™ program, and provide an overview of the Company. A live webcast will be available at  http://www.veracast.com/webcasts/bio/ceoinvestor2017/56115496336.cfm and a webcast replay will be available at the same address approximately one hour after the live webcast presentation. Please log in approximately […]

View Article
InVivo Therapeutics Announces Sixth Patient Conversion in The INSPIRE Study of the Neuro-Spinal Scaffold™

Published: January 24, 2017

-Patient Converts from Complete Paralysis to Partial Paralysis- CAMBRIDGE, Mass. (Jan 24, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the patient enrolled in December in the INSPIRE study of the Neuro-Spinal Scaffold has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury in the time between discharge and the one-month evaluation. This is the sixth out of the eleven patients (54.5% conversion rate) in follow-up to have had an AIS grade improvement. Two patients who have not yet converted are early in follow-up, with conversion possible before the six-month endpoint. The […]

View Article
InVivo Therapeutics Announces New Patient Enrollment into The INSPIRE Study

Published: January 19, 2017

CAMBRIDGE, Mass. (Jan 19, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient has been enrolled into the INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury). Travis Dumont, M.D., an INSPIRE Principal Investigator, performed the implantation on January 16, 2017, approximately 67 hours after the injury occurred. “The implantation procedure of the Neuro-Spinal Scaffold was successful, and the patient is doing well,” Dr. Dumont said. “I look forward to following the patient’s progress going forward.” Mark Perrin, InVivo’s Chief […]

View Article
InVivo Therapeutics Featured in Nationally Syndicated Radio Segment

Published: January 18, 2017

– Health Expert Lisa Davis Interviews CEO and Chairman Mark Perrin – CAMBRIDGE, Mass. (Jan 18, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin was interviewed by Lisa Davis, M.P.H., C.N.C. for a segment on “It’s Your Health” radio during the annual J.P. Morgan Healthcare Conference. Lisa Davis is the creator, host, and producer of “It’s Your Health” radio, which is heard on NPR affiliate and commercial talk radio stations. The show can also be heard on iHeartRadio Talk, TuneIn, Stitcher, iTunes, UberRadio, and TalkStreamLive. “It’s great to be featured on a show that reaches so […]

View Article
InVivo Therapeutics Announces University of New Mexico Hospital as New Site for INSPIRE Study

Published: January 17, 2017

CAMBRIDGE, Mass. (Jan 17, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the University of New Mexico Hospital (UNMH) in Albuquerque, NM has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The University of New Mexico Hospital (UNMH) is the state’s only Level I trauma center. “I am pleased to be joining the INSPIRE study and look forward to the opportunity to safely investigate this innovative experimental therapy,” said Jeremy Lewis, M.D., Assistant […]

View Article
InVivo Therapeutics Announces INSPIRE’S 29th Clinical Site: Rhode Island Hospital

Published: January 10, 2017

CAMBRIDGE, Mass. (Jan 10, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that Rhode Island Hospital in Providence, RI has been added as a clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Rhode Island Hospital is the principal teaching hospital of The Warren Alpert Medical School of Brown University and is the designated Level I trauma center for southeastern New England. “My research interests lie in understanding repair and plasticity within the spinal cord. I look forward […]

View Article
InVivo Therapeutics Announces St. Michael’s Hospital as New Canadian Site for INSPIRE Study

Published: January 9, 2017

CAMBRIDGE, Mass. (Jan 9, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the St. Michael’s Hospital has been added as a Canadian clinical site for The INSPIRE Study: InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. The St. Michael’s Hospital is InVivo’s second site in Toronto and sees over 70,000 emergency visits annually. “My research focuses on engineering applications to neurosurgical procedures with the goal of improving safety and outcome for patients. The INSPIRE study holds much promise for this large unmet […]

View Article
InVivo Therapeutics Responds to PixarBio Announcement

Published: January 3, 2017

CAMBRIDGE, Mass. (Jan 3, 2017) – InVivo Therapeutics Holdings Corp. (NVIV) today issued a response to a PixarBio Corporation press release dated January 3, 2017. The press release claimed that PixarBio had made a $77,000,000 stock offer to acquire InVivo. InVivo Therapeutics Corporation was not privy to the announcement made today and has not had any discussions with PixarBio Corporation nor any other party regarding this matter. Given that the nature of the offer is not credible, InVivo disclaims any obligation to make any additional public statements regarding this or similar proposed transactions from PixarBio. The PixarBio press release contained […]

View Article
InVivo Therapeutics Announces New Patient Enrollment into the INSPIRE Study

Published: December 20, 2016

CAMBRIDGE, Mass. (Dec 20, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that a new patient with a T8-9 fracture dislocation injury has been enrolled into The INSPIRE Study (InVivo Study of Probable Benefit of the Neuro-Spinal Scaffold™ for Safety and Neurologic Recovery in Subjects with Complete Thoracic AIS A Spinal Cord Injury) at the Carolinas Medical Center in Charlotte, NC. Domagoj Coric, M.D., of Carolina Neurosurgery and Spine Associates, Chief of Neurosurgery at the Carolinas Medical Center and a member of the INSPIRE Study Steering Committee, performed the implantation with his partner, Samuel Chewning, M.D. Surgery was performed approximately […]

View Article
InVivo Therapeutics to Present at 2016 Tissue Engineering & Regenerative Medicine International Society Americas Conference

Published: December 12, 2016

CAMBRIDGE, Mass. (Dec 12, 2016) – InVivo Therapeutics Holdings Corp. (NVIV) today announced that the abstract “Demonstration of a Proof-of-Concept Device for Delivering Bioengineered Neural Stem Cell Trails to the Spinal Cord” has been accepted for presentation at the 2016 Tissue Engineering & Regenerative Medicine  International  Society  (TERMIS)  Americas  Annual  Conference  and  Exhibition,  to be held December 11-14, 2016 in San Diego, CA. Artem Kutikov, Ph.D., Research Scientist, will be giving the poster presentation. The abstract is co-authored Dr.  Kutikov,  Richard  Layer,  Ph.D.,  Simon  Moore, Ph.D., Alex Aimetti, Ph.D., Christoph Hofstetter, M.D., Ph.D.,  James  Guest,  M.D.,  Ph.D.,  and  Thomas Ulich, […]

View Article

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on the InVivo website for historical purposes only. InVivo assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.